Elecsys probnp 2 immunoassay

Information on other covariates was collected during Visit 4 from questionnaires and a physical examination, with the exception of education level, which was collected at Visit 1. Smoking status, alcohol intake, and use of antihypertensive medication were self-reported. Weight and height were obtained with the participant wearing light clothing. Body mass index (BMI) was calculated as the weight in kilograms divided by height in meters squared. Blood pressure was measured with a random-zero sphygmomanometer after 5 minutes of rest in the sitting position and was defined as the average of 2 measurements taken. Diabetes was defined as fasting glucose ≥126 mg/dL, nonfasting glucose ≥200 mg/dL, treatment for diabetes, or a self-reported diagnosis of diabetes. Plasma N-terminal prohormone of brain natriuretic peptide (NT-proBNP) was measured on a Cobas e411 analyzer using the Elecsys proBNP II immunoassay (Roche Diagnostics), and high-sensitivity C-reactive protein was measured with an immunonephelometric assay (Siemens Healthcare Diagnostics). Prevalent coronary heart disease (CHD) and HF at Visit 4 were defined as previously described [15 (link)].